Join Growin Stock Community!

Candel therapeutics, inc.CADL.US Overview

US StockHealthcare
(No presentation for CADL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CADL AI Insights

CADL Overall Performance

CADL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CADL Recent Performance

-1.78%

Candel therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CADL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CADL Key Information

CADL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CADL Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Price of CADL

CADL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CADL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
436.42
PB Ratio
3.59
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
436.42
PB Ratio
3.59
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CADL's latest earnings report released?

    The most recent financial report for Candel therapeutics, inc. (CADL) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CADL's short-term business performance and financial health. For the latest updates on CADL's earnings releases, visit this page regularly.

  • How much debt does CADL have?

    As of the end of the reporting period, Candel therapeutics, inc. (CADL) had total debt of 7.21M, with a debt ratio of 0.08. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CADL have?

    At the end of the period, Candel therapeutics, inc. (CADL) held Total Cash and Cash Equivalents of 87.23M, accounting for 0.93 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CADL's EPS continuing to grow?

    According to the past four quarterly reports, Candel therapeutics, inc. (CADL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.21. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CADL?

    Candel therapeutics, inc. (CADL)'s Free Cash Flow (FCF) for the period is -10.35M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 57.51% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.